Join
Live feed
·
PRReleasevia Quantisnow
Madrigal Pharmaceuticals Inc. logo

Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

ByQuantisnow·Wall Street's wire, on your screen.
MDGL· Madrigal Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MDGL (Madrigal Pharmaceuticals Inc.) and more on Quantisnow.